Turns out Galera's radiotherapy complication drug did work after all, and investors are thrilled.

Galera's shares were pummeled in the wake of news that its radiotherapy complication drug flunked a phase 3 study, but now the biotech says the study results were in error, and the treatment did, in fact, work. [ABSTRACT FROM AUTHOR]